Phase 2 Ovarian Cancer Trial, Recruiting NCT05974449 Sponsor: The First Affiliated Hospital with Nanjing Medical University Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 2 Ovarian Cancer Trial, Recruiting

NCT05974449
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with invasive breast cancer (any type), confirmed by a lab test
  • You are a woman aged 18–40 (any hormone receptor status), or aged 41–45 with hormone receptor-negative breast cancer
  • You are expected to receive at least 4 cycles of chemotherapy containing specific drugs (paclitaxel or anthracyclines), along with medications to protect the ovaries
  • You have not yet gone through menopause (including being in the early stages of menopause)
  • You are able to understand the study requirements and are willing and able to follow the treatment plan
  • Your general health and ability to carry out daily activities is good (confirm with trial site)
  • You are willing to take part and have signed a consent form

Who may not be able to join:

  • You have used any vaginal medication in the 3 months before joining the study
  • You have used any antibiotic or anti-infection medication in the 3 months before joining the study
  • You currently have an active infection in the genital area
  • You have previously had another type of cancer
  • For any reason, you are unable to complete all follow-up appointments and treatment as planned by your doctor
  • Certain blood test results or a heart scan show that your liver, kidneys, or heart are not functioning well enough (confirm specific values with trial site)
  • You have a serious blood clotting disorder, a severe ongoing illness, or an infection that cannot be controlled
  • You are not able to make independent decisions for yourself, or you have a mental health condition or addiction that the study doctors feel would make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 30 June 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
24 August 2023
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Vaginal PH; Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov